Literature DB >> 16801566

The effect of glucose variability on the risk of microvascular complications in type 1 diabetes.

Eric S Kilpatrick1, Alan S Rigby, Stephen L Atkin.   

Abstract

OBJECTIVE: It is not known whether glycemic instability may confer a risk of microvascular complications that is in addition to that predicted by the mean blood glucose (MBG) value alone. This study has analyzed data from the Diabetes Control and Complications Trial (DCCT) to assess the effect of glucose variability on the risk of retinopathy and nephropathy in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS: Pre- and postprandial seven-point glucose profiles were collected quarterly during the DCCT in 1,441 individuals. The mean area under the curve glucose and the SD of glucose variability within 24 h and between visits were compared with the risk of retinopathy and nephropathy, having adjusted for age, sex, disease duration, treatment group, prevention cohort, and phase of treatment.
RESULTS: Multivariate Cox regression showed that within-day and between-day variability in blood glucose around a patient's mean value has no influence on the development or progression of either retinopathy (P = 0.18 and P = 0.72, respectively) or nephropathy (P = 0.32 and P = 0.57). Neither preprandial (P = 0.18) nor postprandial (P = 0.31) glucose concentrations preferentially contribute to the probability of retinopathy.
CONCLUSIONS: This study has shown that blood glucose variability does not appear to be an additional factor in the development of microvascular complications. Also, pre- and postprandial glucose values are equally predictive of the small-vessel complications of type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16801566     DOI: 10.2337/dc06-0293

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  110 in total

1.  Translating glucose variability metrics into the clinic via Continuous Glucose Monitoring: a Graphical User Interface for Diabetes Evaluation (CGM-GUIDE©).

Authors:  Renata A Rawlings; Hang Shi; Lo-Hua Yuan; William Brehm; Rodica Pop-Busui; Patrick W Nelson
Journal:  Diabetes Technol Ther       Date:  2011-09-20       Impact factor: 6.118

Review 2.  Measures of glycemic variability and links with psychological functioning.

Authors:  Joseph R Rausch
Journal:  Curr Diab Rep       Date:  2010-12       Impact factor: 4.810

Review 3.  Toward closing the loop: an update on insulin pumps and continuous glucose monitoring systems.

Authors:  Tandy Aye; Jen Block; Bruce Buckingham
Journal:  Endocrinol Metab Clin North Am       Date:  2010-09       Impact factor: 4.741

Review 4.  Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy.

Authors:  L Monnier; C Colette; S Dejager; D R Owens
Journal:  Rev Endocr Metab Disord       Date:  2016-03       Impact factor: 6.514

5.  Evaluation of 1,5-anhydroglucitol, hemoglobin A1c, and glucose levels in youth and young adults with type 1 diabetes and healthy controls.

Authors:  Sanjeev N Mehta; Natalie Schwartz; Jamie R Wood; Britta M Svoren; Lori Mb Laffel
Journal:  Pediatr Diabetes       Date:  2011-11-08       Impact factor: 4.866

6.  Hypoglycemia, but not glucose variability, relates to vascular function in children with type 1 diabetes.

Authors:  Alexia S Peña; Jennifer J Couper; Jennifer Harrington; Roger Gent; Jan Fairchild; Elaine Tham; Peter Baghurst
Journal:  Diabetes Technol Ther       Date:  2012-02-07       Impact factor: 6.118

7.  Interindividual and intraindividual variations in postprandial glycemia peak time complicate precise recommendations for self-monitoring of glucose in persons with type 1 diabetes mellitus.

Authors:  Mette Dencker Johansen; Irene Gjerløv; Jens Sandahl Christiansen; Ole K Hejlesen
Journal:  J Diabetes Sci Technol       Date:  2012-03-01

8.  [Variability of blood glucose concentration and short-term mortality in critically ill patient].

Authors:  S C Ley; D Kindgen-Milles
Journal:  Anaesthesist       Date:  2007-08       Impact factor: 1.041

9.  Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes.

Authors:  I M E Wentholt; W Kulik; R P J Michels; J B L Hoekstra; J H DeVries
Journal:  Diabetologia       Date:  2007-11-10       Impact factor: 10.122

10.  Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials.

Authors:  Roy W Beck; Richard M Bergenstal; Tonya D Riddlesworth; Craig Kollman; Zhaomian Li; Adam S Brown; Kelly L Close
Journal:  Diabetes Care       Date:  2018-10-23       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.